The Cystic Fibrosis Foundation regularly assesses its key research priorities to ensure we are on track to accomplish our mission to cure CF and to provide people with CF the opportunity to lead long lives. Applicants are encouraged to align submissions to these priorities to maximize their potential for being funded.
Site Search
Since the launch of the Infection Research Initiative in 2018, the Cystic Fibrosis Foundation has funded more than $100 million in research to improve the detection, diagnosis, treatment, and outcomes of CF-related infections.
The Cystic Fibrosis Foundation practices venture philanthropy by making strategic investments in companies and technologies with the potential to treat or cure CF. We have a proven track record of accelerating the development of innovative therapies through financial investment, customized research materials, and clinical trial infrastructure.
mRNA therapy is one way to deliver the correct genetic instructions to cells, which would allow them to make functional CFTR protein regardless of an individual’s CF mutations.
Cystic fibrosis is caused by mutations in both copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Scientists are examining whether it is possible to correct the mutations through a process called gene editing.
Cystic fibrosis is caused by mutations in the gene responsible for producing the cystic fibrosis transmembrane conductance regulator (CFTR) protein. For this reason, scientists are exploring ways to provide a correct copy of the gene to treat CF.